FDA APPROVES MERCK’S RSV SHOT DESPITE ALARMING INFANT TRIAL DATA
Comments
Del and Jefferey dive into the troubling numbers behind Merck’s new RSV shot for infants, recently greenlit by the FDA. Trial data revealed higher rates of deaths and severe respiratory illness in vaccinated babies, yet the FDA overlooked this concerning trial data.
AIR DATE: June 19, 2025
Explore
Maybe we can sue the FDA now. Reckless approvals.
Good job at exposing this one, guys.
Looks like the FDA is still a joke.
(Even Purina investigates, after 2 reports of illness, from pet food).
Del, your remarks about RSV conflate the monoclonal antibody shot with the vaccine. Your concerns about the vaccine are valid and the vaccine development has stopped for the moment. However, the monoclonal antibodies, if they stimulate the immune system at all, do not stimulate the immune system the way vaccine does although you allude otherwise. Also, the numbers of severe lower respiratory infections and deaths are unlikely to be statistically significant and are also well below 1%. To be objective, this should be compared with the benefits of receiving the therapy which you didn’t address. We have supported The Highwire for years, but your discussion of this issue is off base and disappoints me in how you pick and choose the science.